Patent · US Active

Methods for treating ocular diseases with brolucizumab

US11098110B2 · kind B2 · utility

5Cited by

2References

6Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Margarita Gekkieva · Basel, CH
Peter Sallstig · Summit, US
Werner Schmidt · Rengsdorf, DE
James Warburton · Chadds Ford, US
Andreas Weichselberger · Basel, CH

Key dates

Filing date	Jun 26, 2018
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Jun 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.